SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-22-027456
Filing Date
2022-11-15
Accepted
2022-11-15 16:00:18
Documents
14
Period of Report
2022-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20221114_8k.htm   iXBRL 8-K 34244
2 EXHIBIT 99.1 ex_447650.htm EX-99.1 117865
  Complete submission text file 0001437749-22-027456.txt   312193

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA navb-20221114.xsd EX-101.SCH 4036
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20221114_def.xml EX-101.DEF 13507
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20221114_lab.xml EX-101.LAB 17661
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20221114_pre.xml EX-101.PRE 13474
8 EXTRACTED XBRL INSTANCE DOCUMENT navb20221114_8k_htm.xml XML 4280
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 221391101
SIC: 2835 In Vitro & In Vivo Diagnostic Substances